<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01714167</url>
  </required_header>
  <id_info>
    <org_study_id>WZMC-2011-8</org_study_id>
    <nct_id>NCT01714167</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke</brief_title>
  <official_title>Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Treatment of Chronic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Texas Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is one of the leading causes of disability in the world, and stem cell -&#xD;
      transplantation provides a promising approach for rehabilitation. The main objective of this&#xD;
      study is to evaluate the efficacy of the intracerebral injection of autologous bone marrow&#xD;
      mesenchymal stem cells in patients with chronic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For many stroke survivors, the best hope is a lengthy program of rehabilitation, followed by&#xD;
      a life-long process of clinical support. However, even with rehabilitation therapy, 50% to&#xD;
      95% of stroke survivors remain impaired. There is thus a great need for new therapeutic&#xD;
      developments for patients with disability after stroke, which is largely unexplored.&#xD;
      Regenerative cell-based therapies offer long-term hope for many patients with stroke, as stem&#xD;
      cells might be possible for dead or injured neural cells to be replaced after acute stroke.&#xD;
      In this study, the investigators will assess the safety and feasibility of intracerebral&#xD;
      transplantation of autologous bone marrow mesenchymal stem cells in patients with chronic&#xD;
      stroke. The neurological outcome will be determined after transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in NIH Stroke Scale at 12 months</measure>
    <time_frame>1, 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of infarct size measured by brain MRI</measure>
    <time_frame>1,6 and 12 months after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>intracerebral stem cell transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group receive conventional stroke treatment that include rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>intracerebral stem cell transplantation</intervention_name>
    <description>Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient</description>
    <arm_group_label>intracerebral stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40-70 ischemia stroke or intracerebral hemorrhage patient&#xD;
&#xD;
          -  With stroke history of more than 3 months, less than 60 months&#xD;
&#xD;
          -  With stable hemiplegia condition&#xD;
&#xD;
          -  NIHSS (NIH stroke scale) score of 7 or more points&#xD;
&#xD;
          -  Patient is stable (normal respiration, afebrile, BP less than mean arterial pressure&#xD;
             of 125 mm of Hg, fasting blood sugar &lt;7 mg, and normal urea/electrolytes for at least&#xD;
             48 hours.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients aged less than 40 or more than 70&#xD;
&#xD;
          -  Lacunar infarction&#xD;
&#xD;
          -  History of neurological disease, head injury or psychiatric disorder with disablity&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Impaired liver function, abnormal blood coagulation, AIDS, HIV, combine other tumor or&#xD;
             special condition&#xD;
&#xD;
          -  Inaccessibility for follow up&#xD;
&#xD;
          -  Unwillingness to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunlin Jin, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of North Texas Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qichuan Zhuge, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qichuan Zhuge, M.D.</last_name>
    <email>zhugeqichuan@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>32500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2012</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Qichuan Zhuge</investigator_full_name>
    <investigator_title>Department of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Bone Marrow Mesenchymal Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

